hrcak mascot   Srce   HID

Pregledni rad

Diabetic retinopathy – risk factors and treatment

Snježana Kaštelan   ORCID icon orcid.org/0000-0002-3983-1157 ; Department for ophtalmological diseases, Klinical hospital Dubrava, Zagreb, Croatia
Martina Tomić ; Department for diabetes complications, Clinics for ophtalmology, University clinics for diabetes, endocrinology and metabolic diseases „Vuk Vrhovac“, Zagreb, Croatia
Višnja Mrazovac ; Clinics for ophtalmological diseases, School of medicine Zagreb, Clinical hospital centre Zagreb, Zagreb, Croatia
Josip Pavan ; Department for ophtalmological diseases, Klinical hospital Dubrava, Zagreb, Croatia
Jasmina Salopek-Rabatić ; Department for ophtalmological diseases, Klinical hospital Dubrava, Zagreb, Croatia
Adrijan Lukenda ; Department for ophtalmological diseases, Klinical hospital Dubrava, Zagreb, Croatia

Puni tekst: hrvatski, pdf (625 KB) str. 48-54 preuzimanja: 1.600* citiraj
APA 6th Edition
Kaštelan, S., Tomić, M., Mrazovac, V., Pavan, J., Salopek-Rabatić, J. i Lukenda, A. (2010). Dijabetička retinopatija – čimbenici rizika i liječenje. Medicina Fluminensis, 46 (1), 48-54. Preuzeto s https://hrcak.srce.hr/48837
MLA 8th Edition
Kaštelan, Snježana, et al. "Dijabetička retinopatija – čimbenici rizika i liječenje." Medicina Fluminensis, vol. 46, br. 1, 2010, str. 48-54. https://hrcak.srce.hr/48837. Citirano 13.04.2021.
Chicago 17th Edition
Kaštelan, Snježana, Martina Tomić, Višnja Mrazovac, Josip Pavan, Jasmina Salopek-Rabatić i Adrijan Lukenda. "Dijabetička retinopatija – čimbenici rizika i liječenje." Medicina Fluminensis 46, br. 1 (2010): 48-54. https://hrcak.srce.hr/48837
Harvard
Kaštelan, S., et al. (2010). 'Dijabetička retinopatija – čimbenici rizika i liječenje', Medicina Fluminensis, 46(1), str. 48-54. Preuzeto s: https://hrcak.srce.hr/48837 (Datum pristupa: 13.04.2021.)
Vancouver
Kaštelan S, Tomić M, Mrazovac V, Pavan J, Salopek-Rabatić J, Lukenda A. Dijabetička retinopatija – čimbenici rizika i liječenje. Medicina Fluminensis [Internet]. 2010 [pristupljeno 13.04.2021.];46(1):48-54. Dostupno na: https://hrcak.srce.hr/48837
IEEE
S. Kaštelan, M. Tomić, V. Mrazovac, J. Pavan, J. Salopek-Rabatić i A. Lukenda, "Dijabetička retinopatija – čimbenici rizika i liječenje", Medicina Fluminensis, vol.46, br. 1, str. 48-54, 2010. [Online]. Dostupno na: https://hrcak.srce.hr/48837. [Citirano: 13.04.2021.]

Sažetak
Diabetic retinopathy, the main microvascular complication of diabetes mellitus, is also estimated to be the leading cause of new blindness in the working population of developed countries. The prevalence of retinopathy in both types of diabetes increases with the duration of diabetes and is highly related to hyperglycemia, hypertension, hyperlipidemia, pregnancy, nephropathy and anemia. The most common causes of visual loss in diabetic patients are diabetic maculopathy and proliferative diabetic retinopathy. Therefore, the main goal of treatment in protecting or improving vision in these patients is to reduce vascular leakage and macular edema, retinal ischemia and growth of fragile new vessels. This would in turn prevent vitreous hemorrhages and tractional retinal detachment. The first step in managing diabetic retinopathy is to reduce the risk of retinopathy development and progression by controlling and treating the underlying risk factors. Laser photocoagulation is the primary method of treatment of macular edema and early stages of proliferative diabetic retinopathy, while pars plana vitrectomy is reserved for severe complications such as severe persistent vitreous hemorrhages or/and tractional retinal detachment. However, more recently, many researches have directed their efforts towards better understanding the microvascular changes in diabetic retinopathy in order to develop more effective pharmacologic prevention and treatment, and determine new treatment strategies. The three major classes of agents currently being studied are: corticosteroids, vascular endothelial growth factor antagonists and agents that are involved in biochemical pathways (protein kinase C inhibitors, somatostatine analogue, aldose reductase and advanced glycation end products inhibitors).

Ključne riječi
diabetic retinopathy; prevention; risk factors; treatment

Hrčak ID: 48837

URI
https://hrcak.srce.hr/48837

[hrvatski]

Posjeta: 2.527 *